Summary. Continuous infusion of glucose with model assessment (CIGMA) is a new method of assessing glucose tolerance, insulin resistance and r-cell function. It consists of a continuous glucose infusion 5mg glucose/kg ideal body weight per min for 60 min, with measurement of plasma glucose and insulin concentrations. These are similar to postprandial levels, change slowly, and depend on the dynamic interaction between the insulin produced and its effect on glucose turnover. The concentrations can be interpreted using a mathematical model of glucose and insulin homeostasis to assess insulin resistance and r-cell function. In 23 subjects (12 normal and 11 with Type 2 (non-insulin-dependent diabetes) the insulin resistance measured by CIGMA correlated with that measured independently by euglycaemic clamp (Rs = 0.87, p < 0.0001). With normal insulin resistance defined as 1, the median resistance in normal subjects was 1.35 by CIGMA and 1.39 by clamp, and in diabetic patients 4.0 by CIGMA and 3.96 by clamp. In 21 subjects (10 normal and 11 Type2 diabetic) the r-cell function measured by CIGMA correlated with steady-state plasma insulin levels during hyperglycaemic clamp at 10 mmol/1 (Rs = 0.64, p< 0.002). The CIGMA coefficient of variability was 21% for resistance and 19% for r-cell function. CIGMA is a simple, non-labour-intensive method for assessing insulin resistance and r-cell function in normal and Type 2 diabetic subjects who do not have glycosuria during the test.
Patients with Type 2 diabetes are usually characterised by the severity of their hyperglycaemia, as assessed by glucose tolerance tests or by fasting plasma glucose measurements. The methods available for assessing the extent to which both/q-cell function and insulin resistance contribute to this hyperglycaemia are not suitable for routine use, and in most diabetic subjects pathophysiology is not assessed. If insulin resistance and deficient/q-cell function could be readily differentiated, it might be possible to predict an individual patient's response to diet, sulphonylurea or insulin therapy.
The feed-back loop between the glucose stimulation of/3-cell secretion and insulin regulation of glucose turnover in the liver, muscle and fat, plays a major r6le in the regulation of fuel supply [1] . Although this is basically a very simple homeostatic system, the interactions are sufficiently complex that the glucose and insulin responses to clinical tests are not easy to assess. Thus, interpretations of the r61es of insulin resistance and r-cell deficiency in maturity-onset diabetic subjects vary [2, 3] . With the aid of mathematical models, the effects of different combinations of insulin resistance and/q-cell deficiency can be predicted [4, 5] .
We have investigated a new method which aims to give a near-physiological stimulus and to interpret the endogenous insulin and glucose responses. A standard, constant, low-dose glucose infusion is given for 60 min. After 30 min the concentrations of insulin and glucose change slowly, and can be compared with reference values obtained from a computer-solved model of insulin/ glucose interaction, assuming different degrees of insulin resistance and /q-cell deficit. This method we call In order to examine whether CIGMA would be a useful method for examining insulin resistance and dcell function, we compared CIGMA's prediction for insulin resistance with estimates derived from (a) the euglycaemic hyperinsulinaemic clamp [6] , (b) the hyperglycaemic clamp [6] , (c) percentage ideal body weight [7] , and (d) fasting plasma insulin concentrations. Similarly, we compared CIGMA's prediction for/3-cell function with values derived from (a) the hyperglycaemic clamp and (b) the intravenous glucose tolerance test.
Methods

The model
Derivation of computer model. The model [5, 8] is based on available physiological data, with the aim of describing quantitatively the relationships between glucose and insulin. The functions used are drawn from experimental physiological data and therefore do not have simple mathematical formulations. Because of this, the equations below are descriptions rather than exact definitions of inter-relationships. The response-curve formats have been published [5, 8] . The variables are summarised in Table 1. A single compartment (V~) of distribution for glucose is used with separate turnover for brain (GB), liver (GO, and insulin-sensitive periphery including muscle and fat (GM). Glucose concentration (G) changes as glucose is added by the liver or infusion and taken up by the periphery and brain: dG GL-GB-GM dt Vc
Brain glucose uptake depends only on glucose concentration and, except at low glucose concentrations, hardly changes from its basal value of 0.42 mmol/min [9] : GB = fB(G) where df__.B > 0 dG (The term fs(G) is the function relating brain glucose uptake to the variable G).
Muscle glucose uptake increases as glucose and 'effective' insulin concentrations (Ie) rise [10] [11] [12] , and decreases as insulin resistance (R) increases:
GM=fM(G, Ie, R) where 0fM>0 0fM>0 0fM<0 0G 0Ie OR Liver production of glucose, which is negative when there is net hepatic uptake, decreases as glucose and 'effective' insulin concentrations rise, and increases as resistance increases [13] [14] [15] . The concentration of insulin to which the liver is exposed is higher than that to which other tissues are exposed, but it is assumed that there is a constant relationship between the two such that increases in pre-hepatic insulin concentration are reflected by increases in post-hepatic insulin concentration. The liver glucose production function is represented thus: GL = fL(G, Ie, R) where 0f--L < 0 0fL < 0 0fL > 0 0G 0Ie OR For the purposes of the model, insulin is physically distributed in one compartment (V0 at plasma concentration (I), and first order disappearance kinetics are assumed. Any effects of insulin, however, are dependent on the 'effective' insulin 'concentration' in a remote ~ tor compartment', which represents the amount of insulin being effective through processes, such as binding to receptors, internalization and enzyme activation.
J. P. Hosker et al.: Continuously infused glucose with model assessment
Insulin is produced by the pancreas and taken up to a significant extent in its first pass through the liver [16] . The model is based on the post-hepatic insulin delivery rate (IDR) with a 4 rain half-life for the exponential disappearance of insulin [17] :
Because there are insufficient quantitative data to describe the processes of the insulin effect from binding to receptor through to alterations in metabolism, we assigned the same value of (In 2)/4 to k~ and to k2, the velocity rate constants to and from the effector compartment: die = klI -k2Ie dt Insulin delivery rate depends upon the glucose concentration profile over the preceding 120 min and upon the pancreatic/3-cell efficiency factor. A sigmoidal, steadily increasing curve describes the relationship between pancreatic activity and glucose concentration, with activity one-sixteenth of maximal in a steady basal state, where glucose concentration is 4 mmol/1 [18] [19] [20] .
fi(G): pancreatic activity function.
fl(4) = 11.3 mU/min (basal) lira fi(G) = 16 x 11.3 (maximum) G---, ~ where dfi > 0 dG A biphasic time course function of insulin release, with a 'first phase' and 'second phase' [21] , represents output as a fraction of basal versus time elapsed since stimulus. The first phase is maximal between 2 and 3 min, dying away by 5 rain, and the second phase gradually builds up to 100% of steady state basal output:
PH (t): phase factor
This multiplies Aft(G), so that the actual output is dependent on time as well as glucose.
The insulin delivery rate is the sum of the most recent increments in pancreatic activity from zero to the value at the time of evaluation multiplied by the corresponding phase magnification factor: IDR(t0) was evaluated by considering the glucose profile G = G(t0-t) where 0<t< 120
An 'inverse' T(G) is defined on the domain G = [0 < G < G(t0)] as follows: min T(G)= 0<t<120 120
if G(t0-t)~=G for any t 0<t<120
d-cell efficiency is the ability of the pancreas to respond to glucose. Insulin resistance represents any defect in responding to insulin. There is no standard way of quantitating these two characteristics, each of which has for simplicity been expressed as a ratio to the mean of values of non-diabetic normal weight subjects aged <35years. Since B multiplies insulin delivery rate (usually by a number < 1 for the diabetics [5, 8] ), it is a measure of/3-cell efficiency and this has been expressed in the CIGMA estimates as percentage of normal/3-cell function. R, the measure of insulin resistance, is the ratio given by the actual level of insulin in a subject divided by the amount of insulin which would achieve the same effect in a non-diabetic 'standard' subject. The accuracy of the derived values depends on the model's assumptions and revised parameters might give improved results.
Final adjustment of computer model. Information concerning/3-cell time responses in man is scanty./3-cell first and second-phase values derived from rats [21] were empirically adjusted to fit observations of human insulin response to an intravenous bolus of glucose; these data were independent of those used elsewhere in this study. The subjects [20] were 10 women (ideal body weight 102-113 %, mean age 32 years) [7] . A bolus of glucose 0.2 g/kg (as a solution of 50 g/100 ml) was infused over 2 rain through an indwelling Teflon cannula (Venflon, Viggo B, Helsingborg, Sweden). The mean increments in glucose and in- Figure 1 A. Without altering any of the data in the model other than the/q-cell time course, a good fit of the model insulin responses was obtained (dashed line, Fig. 1 A) . The model, with its adjusted fl-cell time course, was then used to predict the incremental glucose and insulin values of a continuous infusion of glucose for 60 min, for normal insulin resistance and fl-cell function (dashed line Fig. I B) . This closely fitted the mean incremental glucose and insulin values during continuous infusion of glucose performed in eight young men (aged 22-29 years, 96-107% ideal body weight) (continuous line Fig. 1 B) .
Model prediction of responses for paging degrees of insulin resistance and fl-cellfunction. The model was used to predict a series of mean plasma glucose and insulin responses from 45 to 60 rain of continuous infusion of glucose for differing degrees of insulin resistance and/7-cell function. The concentrations achieved are plotted in Figure 2 .
Investigation methods
The studies were approved by the Oxford District Ethics Committee and all subjects gave informed consent.
Continuous infusion of glucose.
In fasting subjects attending from home, integrated 1 rain samples were taken through a double-lumen Teflon cannula, heparinised at the tip by infusion of heparin through the outer concentric lumen of the cannula (1/100 of the volume of the blood sample) to achieve a final concentration of 50 U heparin/ml in the sample. The hand was kept warm with an electric heating pad so that the blood samples, taken from the indwelling venous cannula on the back of the hand, were similar to arterial blood. The fasting plasma glucose and insulin values were assessed from the mean of the last 13 one-min samples of a 30-rain run-in-period, to allow for the 14-min periodicity of insulin secretion [22] . A continuous intravenous infusion of 5 mg glucose/kg ideal body weight per rain was then started and continued for 60 min. Doses calculated by ideal body weight [7] provide approximately equivalent plasma glucose concentrations, whereas use of actual body weight gives higher plasma glucose concentrations in obese than in normal-weight subjects. Urine was tested for glucose at the end of the infusion. The mean plasma glucose and insulin values over the last 13 observations before the end of the infusion were calculated. In clinical practice, virtually identical results can be obtained by a mean of three samples taken at 50, 55 and 60 rain. 1~ mln oi a ou min intiasion of 5 mg Plasma glucose achieved (retool/I) 
Comparison of fl-cell function and insulin resistance values measured CIGMA with those measured using the hyperglycaemic clamp
Ten normal subjects (aged 22-69 years, 90-113% ideal body weight) and 11 Type2 diabetic patients on diet alone (aged 40-69years, 97-174% ideal body weight) were studied (Table 4) . Each subject was studied twice: once with a CIGMA test as described above, and once with hyperglycaemic clamp lasting 2.5 h at a plasma glucose concentration of 10 mmol/1. No exogenous insulin was infused since it was wished to measure the endogenous insulin response. Otherwise the method was as described for euglycaemic clamp. Each subject was assessed for glycosuria at the end of the clamp. Plasma insulin levels during the last 20 min of the hyperglycaemic clamp were used to assess fl-cell function, expressed as percent of the median value in normal subjects (33 mU/l). Insulin resistance was calculated by dividing the mean plasma insulin over the last 20 min of the hyperglycaemic clamp by the mean glucose infusion rate over the same period, and was normalised to the median for normal-weight, normal subjects. Thus an insulin resistance of I represents 0.18 x [mean plasma insulin (mU/l)]/[mg glucose infused/kg body weight per mini.
Comparison of fl-cell function measured by CIGMA and the intravenous glucose tolerance test
Six of the normal subjects from Table 2 (aged 23-67 years, 90-142% ideal body weight), and five of the diabetic subjects from Table2 (aged 46-68 years, 100-134% ideal body weight) were also studied using the intravenous glucose tolerance test. Subjects were rested overnight in hospital and the same blood sampling technique was used as for the euglycaemic hyperinsulinaemic clamp. Samples were taken each minute, and after a 5-min basal sampling period a glucose bolus of 0.2 g/kg ideal body weight was given over 2 rain through a second Teflon cannula (Venflon) inserted into an antecubital vein. Sampling was continued for 45 rain after the bolus infusion. The mean plasma insulin concentration from 10 to 30 rain after the start of the bolus infusion was used as the measure offl-cell function.
Reproducibility of insulin resistance and fl-cell function as measured by CIGMA
Nine normal subjects (aged 22-29 years, 96-107% ideal body weight) and nine Type2 diabetic subjects treated by diet only (aged 46-68 years, 106-188% ideal body weight) had two CIGMAs on separate days within 3 weeks. The fasting plasma glucose was 4.2+ 0.2 mmol/1 in normal subjects and 6.2 + 0.9 mmol/1 in diabetic subjects. Subjects were asked to adhere to the same diet over this time.
The values from CIGMA for insulin resistance and fl-ceU function were compared on the two occasions and a coefficient of variation of duplicates was calculated for each of these measures using the formula:
Assays and statistical analysis
Insulin and C-peptide levels were assayed by charcoal-phase separation radioimmunoassay [24] , with a between-assay coefficient of variation of 11-16%. Glucose was measured by a glucose-oxidase method (Boehringer GOD-Perid, Boehringer Corporation London, Lewes, Sussex, UK). The results were analysed using non-parametric (Spearman rank correlation coefficient) and parametric statistical tests (Student's t-test).
Results
Plasma glucose responses to CIGMA
The mean plasma glucose level achieved over the last 15 rain of the 60 min infusion correlated with the fasting plasma glucose for the total of 72 CIGMAs performed (38 normal and 34diabetic subjects), and provided a (Fig. 3) . The plasma glucose of normal subjects rose from a fasting value of 4.4_+0.4mmol/1 (mean+_SD) to a 45-60min value of 7.7+0.8mmol/1. The plasma glucose of the diabetic subjects rose from 6.2 + 1.1 fasting to 10.4 _+ 1.3 mmol/1. The bi-variate regression line for all subjects was: (plasma glucose achieved at 45-60min)=(fasting plasma glucose • 1.46) + 1.2.
Comparison of insulin resistance measured by CIGMA with that measured by euglycaemic hyperinsulinaemic clamp (Table 2)
Quality of euglycaemic hyperinsulinaemic clamps. The median duration of the clamps in normal subjects was 130min (range 110-164min) and in Type2 diabetic subjects was 132 rain (range 100-210 rain). The range of mean plasma insulin values over the last 20 rain of each clamp was 26.4-84.2 mU/1 with a median of 38.3 mU/1. Mean_+ SD fasting plasma C-peptide in normal subjects was 0.36_+0.13nmol/1, and was suppressed to 0.09 _+ 0.07 nmol/1 over the last 20 min of each subject's clamp. In diabetic subjects, fasting C-peptide was 0.57 + 0.18 nmol/1, and suppressed to 0.16 -+ 0.10 nmol/1 over the last 20 min.
The mean -+ SD of individual subjects' mean plasma glucose concentrations over the last 40 rain of the euglycaemic clamp (20values for each subject) was 4.5 + 0.1 mmol/1. The mean_+ SD of individual subjects' coefficients of variation of the plasma glucose over the same period was 5.2 _+ 2.0%.
Comparison of insulin resistance measurements. The in-
sulin resistance measured by CIGMA correlated with that measured using the euglycaemic hyperinsulinaemic clamp, in normal subjects (Spearman rank correlation coefficient Rs=0.79, p< 0.002), diabetic subjects (R~=0.91, p<0.002) and in both groups combined (R~ = 0.87, p< 0.0001) (Fig. 4) . The relationship between the values by the two methods in diabetic subjects was non-linear, with higher values in five subjects when measured by the euglycaemic hyperinsulinaemic clamp. These subjects had high fasting plasma insulin concentrations (9-37 mU/1). The range of insulin resistance measured by both methods in normal subjects was approximately 0.5-3.0. The median resistance in normal subjects was 1.35 by CIGMA and 1.45 by euglycaemic hyperinsulinaemic clamp, and in diabetic subjects was 3.9 by CIGMA and 4.1 by the clamp. No subject had glycosuria exceeding 5 retool/1 at the end of the CIG-MA tests.
Comparison of insulin resistance measured by CIGMA and that measured by hyperglycaemic clamp (Table 4)
Quality ofhyperglycaemic clamps. The mean _+ SD of the individual subjects' mean plasma glucose concentrations over the last 40 min of the clamp (20 values for each subject) was 9.9 + 0.2 mmol/1, with a mean coefficient of variation of 3.6%. No subject had glycosuria exceeding 5 mmol/1.
Comparison of insulin resistance measurement. The
CIGMA estimate of insulin resistance correlated with that measured by hyperglycaemic clamp in normal subjects alone (1%=0.75, p<0.02), in diabetic subjects alone (1% = 0.82, p < 0.005) and in both groups together (1% = 0.78, p < 0.0001 ; Fig. 4 ). The range of insulin resistance values in normal subjects was 0.7-3.2 by CIGMA, and 0.4-1.9 by hyperglycaemic clamp. The median resistance in normal subjects was 1.6 by CIGMA and 0.97 by hyperglycaemic clamp, and in diabetic subjects it was 2.8 by CIGMA and 1.1 by hyperglycaemic clamp.
Comparison of different measurements of insulin resistance with body weight and fasting plasma insulin
Obesity, expressed as percent ideal body weight, was correlated with insulin resistance measured by euglycaemic hyperinsulinaemic clamp in normal subjects alone (1% = 0.87, p < 0.0001), in diabetic subjects alone (1% = 0.54, NS) and in both groups together (Rs = 0.73, p < 0.0001 ; Fig. 5 A) . The relationship between insulin resistance determined by CIGMA and body weight is shown in the lower part of Figure 5A ; in normal subjects alone the correlation coefficient was 1%=0.51 (p< 0.05), in diabetic subjects alone 1% = 0.52 (NS), and in both groups together 1% = 0.59 (p< 0.002).
Fasting plasma insulin correlated with insulin resistance measured by the euglycaemic hyperinsulinaemic clamp in normal subjects alone (1%=0.83, p<0.0006), in diabetic subjects alone (R~=0.79, p<0.004) and in both groups together (1%=0.81, p<0.0001; Fig.5B ). Fasting plasma insulin correlated with CIGMA resistance in normal subjects (1% = 0.75, p < 0.003), in diabetic subjects (1% = 0.80, p < 0.004) and in both groups together (1% = 0.84, p < 0.0001).
The relationships between CIGMA estimates of insulin resistance and either ideal body weight or fasting plasma insulin concentration were more linear than the relationships between euglycaemic hyperinsulinaemic clamp estimates of insulin resistance and these indices.
Reproducibility of estimate of insulin resistance by CIGMA
The coefficients of variation of the CIGMA value for insulin resistance, from paired tests in nine normal and nine diabetic subjects, were 20% and 21%, respectively.
The repeat CIGMA profiles for the nine normal subjects were segregated according to the member of each pair that gave the highest achieved insulin value. Throughout the infusion, the mean insulin and glucose profiles were higher in the tests with higher achieved insulin concentrations than in those with lower achieved insulin concentrations (Fig. 6) . The difference in fasting Comparison of p-cell function measured by CIGMA with that measured by hyperglycaemic clamp fl-cell function measured by CIGMA correlated significantly with the fl-cell function measured by the hyperglycaemic clamp in diabetic subjects (1%=0.80, p< 0.005) but not in normal subjects alone (1% = 0.45). For both groups together, the correlation was 1% = 0.64 (p < 0.002; Fig. 7 B) . The ranges of values for fl-cell function in normal subjects were 30-109% by CIGMA and 45-240% by hyperglycaemic clamp (corresponding to plasma insulin 14.9-79.4 mU/1). The median values for fl-cell function in normal subjects were 70% by CIGMA and 100% by hyperglycaemic clamp, and in diabetic patients were 51% by CIGMA and 69% by hyperglycaemic clamp.
Comparison of fl-cell function measured by CIGMA with that measured by intravenous glucose tolerance test
The ranges of fl-cell function measured by CIGMA in six normal and six diabetic subjects were 35-145% (me- subjects taken separately correlated R~ = 0.71 (NS) and 0.98 (p < 0.01), respectively and for both groups together (R~) was 0.84, p < 0.002; Fig. 7 A) .
Reproducibility of estimate of fl-cell function by CIGMA
When fl-cell function was estimated by CIGMA in the nine normal men studied on two different days, one subject on one occasion did not increase his plasma glucose above 4 mmol/l and his data could not be read from the graph. The duplicate values of the remaining eight subjects correlated (R~ = 0.65, p< 0.05), with a coefficient of variation of 19%. The coefficient of variation for fl-cell function on duplicate DIGMA tests in nine diabetic subjects was also 19%.
Discussion
Principles of CIGMA
The steady-state mathematical model [5, 8] has been extended in this study to assess the glucose and insulin responses to a glucose infusion. A model incorporating the best available physiological data is used to interpret the observed responses. This incorporates more information on the body's metabolism than the minimal modelling approach using an intravenous glucose bolus [4] . In addition, a near-physiological glucose load is given, and the slowly changing homeostasis is more easily assessed. Both these modelling methods and the hyperglycaemic clamp examine the response to a patient's endogenous insulin secretion, and this approach may be superior to the euglycaemic hyperinsulinaemic clamp or insulin suppression test methods [6, 25] , which use supraphysiological doses of insulin into the peripheral rather than the portal circulation. The model includes response curves for different levels of glycaemia, so theoretically the insulin resistance and/?-cell function values derived from CIGMA are independent of the glucose levels achieved. However, the model assessment assumes that the parameters of the model are relevant to the subjects studied. These assumptions include equality of insulin resistance at the liver and the periphery [26, 27] and that the reduction in/?-cell function in diabetes is a quantitative decrease (i.e., decrease in Vmax) [20] . Thus, the model may not be relevant in certain special situations; e.g. if there were a change of shape of the/?-cell dose response curve. The use of the model assumes that the insulin assay used is accurate, giving a normal mean fasting plasma insulin of 5 mU/1.
CIGMA as a test of glucose tolerance
Without any modelling of its results, the simple infusion of glucose can be considered as a test of glucose tolerance, analogous to the oral glucose tolerance test. The relationship between the fasting plasma glucose and the plasma glucose achieved between 45 and 60min of CIGMA appears to be similar to that between the fasting plasma glucose and 2-h glucose value after an oral glucose tolerance test. Thus, a fasting plasma glucose of 7 retool/1 corresponds to a mean 45-60 min plasma glucose of 11.4mmol/1 during CIGMA. For comparison, the World Health Organisation diagnostic criteria for diabetes mellitus require a fasting capillary blood glucose more than 7mmol/1 or a value more than 11 retool/l, 2 h after a 75-g glucose load [28] .
Validation of assessment of insulin resistance by CIGMA
Insulin resistance as measured by CIGMA correlated with that measured by euglycaemic hyperinsulinaemic clamp. This relationship appeared to be non-linear in the diabetic subjects with the most marked insulin resistance (Fig. 4) . This is probably due to an over-estimation by the clamp method, as we used a near-physiological dose of infused insulin, providing a median peripheral insulin concentration of 38 mU/1, and this may have been insufficient to suppress hepatic glucose production in insulin-resistant patients who had high fasting insulin concentrations. By contrast, the insulin resistance values obtained by CIGMA correlated in a nearlinear manner with insulin resistance measured by the hyperglycaemic clamp. This may have reflected more complete suppression of hepatic glucose production by endogenous portal insulin during the hyperglycaemic clamp than during the euglycaemic hyperinsulinaemic clamp. The latter showed non-linearity with independent correlates of insulin resistance (fasting plasma insulin and body weight), whereas CIGMA resistance values correlated in a linear manner with these indices. A higher insulin dose in the euglycaemic clamp would probably have given more concordance [6] , but there is a theoretical risk that pharmacological rather than physiological actions of insulin would then be assessed. Euglycaemic hyperinsulinaemic clamps may have other disadvantages as compared with CIGMA, including the fact that different subjects achieve different plasma insulin concentrations despite the same insulin infusion rate. In CIGMA, allowance is made for different insulin concentrations, and for separate hepatic and peripheral effects of insulin. This is more physiological than the euglycaemic clamp and insulin suppression tests [6, 29] which deliver insulin to the periphery.
There was a significant correlation between insulin resistance (measured either by CIGMA or by euglycaemic clamp) and body weight when the whole group of normal and diabetic subjects was considered, but not among diabetic subjects alone. Although the more obese diabetic subjects tended to be more insulin resistant, there was not a close correlation between the two variables. There may be inherent differences between subjects in respect of insulin resistance, as well as additional insulin resistance associated with hyperglycaemia [30, 31] . CIGMA might have a role in screening diabetic subjects to identify those who are most insulin resistant and perhaps have more to gain by weight reduction.
CIGMA estimate of /3-cell function
There was a significant correlation between the CIG-MA and hyperglycaemic clamp estimates of/3-cell function in diabetic but not in normal subjects. This difference contrasts with the ability of CIGMA to correlate with the insulin resistance values found in the clamp studies for normal and diabetic subjects alike. There may be important differences between normal and diabetic subjects in the glucose-insulin stimulus-response relationship of the/3-cell, such that the model assumptions apply more to diabetic than to normal subjects. The correlation between CIGMA and hyperglycaemic clamp estimates of/3-cell function in diabetic subjects was linear.
Comparison of the CIGMA estimate for/3-cell function with the 10-30 min second phase response in the intravenous glucose tolerance tests also revealed a significant correlation, which appeared to be linear.
CIGMA could be used with C-peptide instead of insulin measurements. This may be advantageous as it assesses pancreatic secretion rather than the post-hepatic delivery rate and plasma proinsulin usually cross-reacts less with C-peptide than insulin assays. On the other hand, direct measurement of plasma insulin levels, the bio-active principle in the periphery, may have some advantages in assessing insulin resistance.
Insulin secretion is usually assessed by oral glucose tolerance tests. These are complex to analyse, partly because of variable gastric emptying, unquantified neural and enteric stimuli and a non-standard glycaemic stimulus to the/3 cells. Although an intravenous glucose tolerance test is simpler, its value in assessing/3-cell function and especially insulin resistance is uncertain. Mathematical models have been used to assess first and second phase/3-cell responses [4] . These are rarely used in practice, and the intravenous glucose tolerance test has the theoretical problems of providing a rapid onset, supra-physiological stimulus, where mixing transients, rate of infusion, and timing of samples may all be critical.
Reproducibility of CIGMA estimate of insulin resistance and fl-cell function
The variability of CIGMA could at best be as small as the inter-assay coefficient of variation of the insulin radioimmunoassay (which is 11-16% in this laboratory), as the plasma insulin value is used directly in the assessment. This is in contrast to the euglycaemic clamp [5] and the insulin suppression tests [25, 29] where the same amount of exogenous insulin is infused into each subject and the calculation of insulin resistance is made from glucose infusion data only. The euglycaemic clamp method can be subject to subtle bias from different experimenters' intentions, as shown by Greenfield et al. [32] who obtained a coefficient of variation of 17% for the difference in metabolic clearance rate between pairs of clamps. This is similar to our value for the coefficient of variation of 20% for insulin resistance measured by CIGMA in pairs of tests on nine normal subjects, and 21% in nine diabetic subjects.
The day-to-day variation in the value given to insulin resistance assessed by any method is dependent on two factors: changes in the body's insulin resistance from day-to-day, and the precision of the method used. For an individual, insulin resistance is not at a constant level but varies according to factors, such as preceding exercise and food intake. The comparison of paired mean CIGMA profiles in the nine normal subjects, segregated by the day with the higher achieved insulin concentrations, showed how fasting glucose and insulin concentrations on the one hand, and stimulated concentrations on the other, varied similarly from day-today. This suggests that these patients were really more insulin resistant on the day of the higher achieved insulin level test, whether assessed by fasting or by stimulated glucose-insulin results.
r-cell function is also likely to vary from day-to-day, especially under the influence of diet [33] . This will similarly decrease the apparent precision of the CIGMA measure of/3-cell function. The variation of insulin resistance is also likely to influence r-cell function and vice versa.
Practical aspects
In its most simple form, CIGMA entails a 60-min infusion of glucose with glucose and insulin assay of three plasma samples taken during the last 15 min to take into account the pulsatility of insulin secretion [22] . The insulin resistance and r-cell function are then read from a chart using the mean glucose and insulin levels. It is also possible to obtain estimates of/3-cell function and insulin resistance from model assessment of basal plasma insulin and glucose concentrations [5, 8, 34] , but the re-suits are less precise than by CIGMA. Clamp techniques are widely used, but are extremely labour-intensive and, if a closed loop feedback system is used, require expensive equipment.
The CIGMA test has potential as a routine test for glucose tolerance and for assessing the pathophysiology of Type 2 diabetic patients, provided they do not have glycosuria during the test.
